BAARERSTRASSE 14, ZUG, V8
Provides Business Update and Reports First Quarter 2026 Financial Results
Annual Report to Security Holders
Prices Upsized Convertible Senior Notes Offering
Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
Other Events
Provides Business Update and Reports Third Quarter 2025 Financial Results
CRISPR Therapeutics Files Prospectus Supplement for $600 Million Offering
Provides Business Update and Reports Second Quarter 2025 Financial Results
Q1
FY 2024
Q3
Q2
FY 2023
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
S-3ASR
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Amended Schedule 13G - Ownership Report
Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Submission Upload
Correspondence